Cargando…

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study: Palivizumab prophylaxis in children with congenital heart disease

BACKGROUND: In children with congenital heart disease (CHD) respiratory syncytial virus (RSV) infection may have a severe course, with increased risk of morbidity and mortality, requiring hospital admission and intensive care. The aim of the present study was to evaluate the effect of prophylaxis wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ratti, Chiara, Greca, Anna della, Bertoncelli, Deborah, Rubini, Monica, Tchana, Bertrand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835345/ https://www.ncbi.nlm.nih.gov/pubmed/36631870 http://dx.doi.org/10.1186/s13052-022-01399-z

Ejemplares similares

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
por: Chiu, Shuenn-Nan, et al.
Publicado: (2022)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease
por: Mohammed, Mohammed Hassan A., et al.
Publicado: (2021)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Risk Factors, Prophylaxis, and Treatment of Venous Thromboembolism in Congenital Heart Disease Patients
por: Silvey, Michael, et al.
Publicado: (2017)

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
por: Manini, Mariana Bueno, et al.
Publicado: (2021)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Awareness of infective endocarditis prophylaxis in parents of children with congenital heart disease: A prospective survey
por: Nath, Parrimala, et al.
Publicado: (2008)

Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases
por: Kim, Ah Young, et al.
Publicado: (2016)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Respiratory infections in children up to two years of age on prophylaxis with palivizumab
por: Monteiro, Ana Isabel M. P., et al.
Publicado: (2014)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

COVID19: potential cardiovascular issues in pediatric patients
por: Bertoncelli, Deborah, et al.
Publicado: (2020)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009)

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
por: Fernández, Pilar, et al.
Publicado: (2010)

Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab Prophylaxis
por: Oncel, Mehmet Yekta, et al.
Publicado: (2013)

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports
por: Cutrera, Renato, et al.
Publicado: (2019)

Sleep in Infants with Congenital Heart Disease
por: Ykeda, Daisy Satomi, et al.
Publicado: (2009)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
por: de Souza, Roseane Porfírio, et al.
Publicado: (2019)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Compliance with RSV prophylaxis: Global physicians’ perspectives
por: Anderson, Kari S, et al.
Publicado: (2009)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Prevalence of congenital anomalies in newborns with congenital heart disease diagnosis
por: Egbe, Alexander, et al.
Publicado: (2014)

Congenital heart disease
Publicado: (1997)

Congenital Heart Disease
por: Gilchrist, A. Rae
Publicado: (1948)

Congenital Heart Disease
Publicado: (1940)

EDUCATIONAL SERIES IN CONGENITAL HEART DISEASE: Prenatal diagnosis of congenital heart disease
por: Hunter, Lindsey E, et al.
Publicado: (2018)

Does RSV prophylaxis prevents future recurrent wheeze in preterm infants?
por: Ignacio, Lena, et al.
Publicado: (2013)

Heart Transplantation in Congenital Heart Disease
por: Parisi, Francesco
Publicado: (2011)

Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia
por: Al Aql, Fahad, et al.
Publicado: (2016)

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen
por: Claydon, Jennifer, et al.
Publicado: (2017)

Ortner’s Syndrome in an Infant With Congenital Heart Disease
por: Murillo-Deluquez, Marcelino, et al.
Publicado: (2022)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

EDUCATIONAL SERIES IN CONGENITAL HEART DISEASE: Three-dimensional echocardiography in congenital heart disease
por: Simpson, John M, et al.
Publicado: (2019)

EDUCATIONAL SERIES IN CONGENITAL HEART DISEASE: Cardiovascular MRI and CT in congenital heart disease
por: Pushparajah, Kuberan, et al.
Publicado: (2019)

Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing
por: Coletta, Elio, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_h41t95jojuteleokqcp3cuoalh